NYSE:RCUS

Arcus Biosciences Stock Insider Trading

etoro logo Buy RCUS
*Your capital is at risk
$23.86
-0.610 (-2.49%)
At Close: Jun 03, 2026

Arcus Biosciences Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -59.23. In total, the insiders bought 2.15M and sold 639.53K RCUS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
-59.23
Buy 2.15M shares
Sell 639.53K shares
55% Buy Activity
Strong Negative Correlation
Buy Signal Low Confidence
Jan 23, 2026

Analysis Breakdown:

  • Signal is highly questionable due to a strongly contradictory negative Insider Power Score of -59.23.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Jun 01, 2026
Sell
Common Stock
S-Sale
Azoy Alexander
Chief Accounting Officer
Officer 2 562
Value: $66.0K
May 11, 2026
Sell
Common Stock
S-Sale
Goeltz Ii Robert C.
Chief Financial Officer
C-Suite Officer 7 763
Value: $199.0K
Jan 23, 2026
Buy
Stock Option (right to buy)
A-Award
Jarrett Jennifer
Chief Operating Officer
C-Suite Officer 126 000
Value: $2.79M
Jan 23, 2026
Buy
Common Stock
A-Award
Goeltz Ii Robert C.
Chief Financial Officer
C-Suite Officer 24 000
Value: $531.1K
Jan 23, 2026
Buy
Stock Option (right to buy)
A-Award
Goeltz Ii Robert C.
Chief Financial Officer
C-Suite Officer 96 000
Value: $2.12M
Jan 23, 2026
Buy
Stock Option (right to buy)
A-Award
Tang Carolyn C.
General Counsel
Officer 96 000
Value: $2.12M
Jan 23, 2026
Buy
Stock Option (right to buy)
A-Award
Jaen Juan C.
President
CEO / President 126 000
Value: $2.79M
Jan 23, 2026
Buy
Common Stock
A-Award
Azoy Alexander
Chief Accounting Officer
Officer 21 050
Value: $465.8K
Jan 23, 2026
Buy
Stock Option (right to buy)
A-Award
Markus Richard
Chief Medical Officer
Officer 96 000
Value: $2.12M
Jan 23, 2026
Buy
Common Stock
A-Award
Markus Richard
Chief Medical Officer
Officer 24 000
Value: $531.1K
Jan 23, 2026
Buy
Common Stock
A-Award
Rosen Terry J
Chief Executive Officer
CEO / President 79 000
Value: $1.75M
Jan 23, 2026
Buy
Stock Option (right to buy)
A-Award
Rosen Terry J
Chief Executive Officer
CEO / President 315 000
Value: $6.97M
Jan 23, 2026
Buy
Common Stock
A-Award
Jaen Juan C.
President
CEO / President 31 000
Value: $686.0K
Jan 23, 2026
Buy
Common Stock
A-Award
Tang Carolyn C.
General Counsel
Officer 24 000
Value: $531.1K
Jan 23, 2026
Buy
Stock Option (right to buy)
A-Award
Azoy Alexander
Chief Accounting Officer
Officer 14 050
Value: $310.9K
Jan 23, 2026
Buy
Common Stock
A-Award
Jarrett Jennifer
Chief Operating Officer
C-Suite Officer 31 000
Value: $686.0K
Jan 08, 2026
Sell
Common Stock
G-Gift
Rosen Terry J
Chief Executive Officer
CEO / President 35 000
Value: $0
Jan 05, 2026
Sell
Common Stock
S-Sale
Jaen Juan C.
President
CEO / President 29 670
Value: $633.2K
Jan 05, 2026
Sell
Common Stock
S-Sale
Jaen Juan C.
President
CEO / President 2 053
Value: $45.9K
Jan 05, 2026
Sell
Common Stock
S-Sale
Jaen Juan C.
President
CEO / President 100
Value: $2K
Dec 31, 2025
Sell
Common Stock
S-Sale
Goeltz Ii Robert C.
Chief Financial Officer
C-Suite Officer 6 552
Value: $153.2K
Dec 30, 2025
Sell
Common Stock
G-Gift
Rosen Terry J
Chief Executive Officer
CEO / President 2 400
Value: $0
Dec 18, 2025
Sell
Common Stock
S-Sale
Azoy Alexander
Chief Accounting Officer
Officer 4 343
Value: $96.6K
Dec 17, 2025
Sell
Common Stock
S-Sale
Jarrett Jennifer
Chief Operating Officer
C-Suite Officer 9 983
Value: $221.2K
Dec 17, 2025
Sell
Common Stock
S-Sale
Goeltz Ii Robert C.
Chief Financial Officer
C-Suite Officer 5 960
Value: $132.1K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT ARCUS BIOSCIENCES INC.
Arcus Biosciences
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Pha...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE